Stocks · Healthcare · Biotechnology
Theravance Biopharma Inc TBPH
$17.03 +0.00% Close, Sep 25, 2026 · NASDAQ · Market cap $882.6M
Low risk
Next earnings report: Nov 10, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Diluted EPS over the last four quarters was $1.01, up 322.4% year over year.
- Operating margin widened to 4.5% from -48.2% a year earlier.
- Revenue over the last four quarters was $104.3M, up 35.1% from a year earlier, slowing from 68.2% a quarter earlier.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 22%
- EPS growth (TTM, YoY)Top 5%
- FCF growth (TTM, YoY)Bottom 14%
- Revenue growth, 3-year CAGRTop 23%
- Revenue growth accelerationBottom 9%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 31%
- Gross marginTop 19%
- Operating marginTop 35%
- Cash conversion (OCF / net income)Bottom 21%
- Accruals (lower is better)Bottom 16%
- Net debt / EBITDA (lower is better)Top 12%
- Interest coverTop 29%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 7%
- Free-cash-flow yieldTop 15%
- EBITDA / enterprise valueTop 10%
- Sales / enterprise valueBottom 39%
- P/E vs own 5-year history (lower is better)Bottom 18%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 49%
- 6-month returnTop 45%
- 1-year return vs S&P 500Top 44%
- Distance from 52-week highTop 30%
- Trend checklist (0–4)Bottom 38%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 5%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyBottom 2%
- Upside to consensus price targetBottom 10%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 1%
- Maximum drawdown, 3 yearsTop 8%
- Beta vs S&P 500 (lower is better)Top 45%
- Net debt / EBITDA (lower is better)Top 12%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 68.2% | 35.1% | ↓ |
| Gross margin | 47.3% | 89.4% | ↑ |
| Operating margin | -48.2% | 4.5% | ↑ |
| FCF margin | 317.0% | 49.7% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 35.1% | 68.2% | ↓ | Top 22% |
| EPS growth (TTM, YoY) | 322.4% | — | Top 5% | |
| Gross margin | 89.4% | 47.3% | ↑ | Top 19% |
| Operating margin | 4.5% | -48.2% | ↑ | Top 35% |
| Net margin | 51.6% | 16.9% | ↑ | — |
| Free-cash-flow margin | 49.7% | 317.0% | ↓ | — |
| Return on invested capital | 0.9% | — | Top 31% | |
| Revenue growth, 3-year CAGR | 27.9% | — | Top 23% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 0.96×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- 0.4%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 18.7%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -42.1 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- -2.65×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- 4.0×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- 0.21%
- Shareholder yield
- 0.21%
- Share count change, 1 year
- +1.9%
- Share count change, 3-year CAGR
- -3.0%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 11, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 2 of 8
- Average EPS surprise, last 4
- -100.0%
- Average 2-day reaction, last 8
- +0.9%
- Positive 20 days after report
- 7 of 8
Analysts
- Consensus price target
- $17.00
- Target vs current price
- -0.2%
- Analysts with a rating
- 17
- Share rating Buy or Strong Buy
- 24%
- Consensus rating
- Hold
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 10, 2026 | -251.7% | -0.1% | +0.2% | +0.9% | — |
| May 7, 2026 | -443.6% | +0.5% | -1.6% | -3.4% | -0.4% |
| Mar 19, 2026 | -86.4% | +1.3% | +10.6% | +21.3% | +20.3% |
| Nov 10, 2025 | +133.3% | +2.2% | +17.9% | +22.8% | +32.7% |
| Aug 12, 2025 | +1370.6% | +4.6% | +19.4% | +20.7% | +29.4% |
| May 8, 2025 | -31.2% | -0.9% | -15.8% | +7.8% | +12.3% |
| Feb 26, 2025 | -81.2% | +1.2% | +1.4% | +3.8% | +4.9% |
| Nov 12, 2024 | -12.6% | -1.9% | +4.5% | +11.0% | +0.4% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 10, 2026 | -$0.11 | $0.07 | -251.7% | $20.7M |
| May 7, 2026 | -$0.10 | $0.03 | -443.6% | $17.7M |
| Mar 19, 2026 | $0.06 | $0.44 | -86.4% | $45.9M |
| Nov 10, 2025 | $0.04 | -$0.12 | +133.3% | $20.0M |
| Aug 12, 2025 | $1.08 | -$0.09 | +1370.6% | $26.2M |
| May 8, 2025 | -$0.27 | -$0.21 | -31.2% | $15.4M |
| Feb 26, 2025 | -$0.31 | -$0.17 | -81.2% | $18.8M |
| Nov 12, 2024 | -$0.26 | -$0.23 | -12.6% | $16.9M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 16.8× | 7.3× | 78th | Top 7% |
| P/E (forward) | 5.9× | — | — | — |
| EV / EBITDA | 10.2× | — | — | Top 10% |
| EV / Sales | 6.72× | — | — | Bottom 39% |
| Free-cash-flow yield | 5.87% | — | — | Top 15% |
| Earnings yield | 5.95% | — | — | Top 7% |
P/E over the past five years
Range 0.9× – 51.8× since Sep 30, 2022. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
What moved the stock over the past year
- Price return, 1 year
- +21.2%
- Earnings per share growth (TTM)
- +322.4%
- Change in P/E multiple
- -67.7%
Most of the move came from earnings growth.
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✓ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 71
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- +0.1%
- 200-day average slope (20 days)
- -0.8%
- Distance from 50-day average
- +0.4%
- Distance from 200-day average
- -0.8%
- RSI (14)
- 53.2
- Relative volume
- 0.00×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 2.9%
- Volatility vs own 5-year history
- 0th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.02
- Correlation with S&P 500
- 0.35
- Current drawdown from 1-year high
- -17.9%
- Maximum drawdown, 3 years
- -34.6%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Apr 21, 2021 | Sep 15, 2021 | -69.9% | 102 days | Not yet recovered |
| Feb 9, 2021 | Feb 26, 2021 | -19.7% | 12 days | 9 days (Mar 11, 2021) |
| Oct 27, 2020 | Nov 23, 2020 | -19.5% | 19 days | 52 days (Feb 9, 2021) |
| Sep 18, 2020 | Sep 30, 2020 | -17.0% | 8 days | 7 days (Oct 9, 2020) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $882.6M
- P/E (TTM)
- 16.8
- EPS, diluted (TTM)
- $1.01
- Revenue (TTM)
- $104.3M
- 52-week range
- $13.08 – $21.03
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $55.3M | $51.3M | $57.4M | $64.4M | $107.5M |
| Gross profit | -$138.3M | -$12.0M | $16.8M | $26.7M | $101.9M |
| Operating income | -$257.8M | -$92.0M | -$56.0M | -$46.9M | -$13.2M |
| Net income | -$199.4M | $872.1M | -$55.2M | -$56.4M | $105.9M |
| EPS (diluted) | -$2.87 | -$1.26 | -$1.00 | -$1.15 | $2.06 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $16.9M | $18.8M | $15.4M | $26.2M | $20.0M | $45.9M | $17.7M | $20.7M |
| Net income | -$12.7M | -$15.5M | -$13.6M | $54.8M | $3.6M | $61.0M | -$4.9M | -$5.9M |
| EPS (diluted) | -$0.26 | -$0.31 | -$0.27 | $1.08 | $0.07 | $1.15 | -$0.10 | -$0.11 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$207.9M | -$187.0M | -$27.0M | -$11.5M | $238.5M |
| Capital expenditure | -$3.4M | -$572,000 | -$2.5M | -$332,000 | -$42,000 |
| Free cash flow | -$211.3M | -$187.6M | -$29.5M | -$11.9M | $238.5M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $99.1M | -$132.3M | -$199.6M | -$3.0M | -$3.2M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $387.7M
- Total assets
- $469.8M
- Total liabilities
- $180.1M
- Total debt
- $38.6M
- Net debt
- -$181.2M
- Shareholders’ equity
- $289.7M
As of Jun 30, 2026 (filed Aug 11, 2026).